Mesoblast Limited develops allogeneic cellular medicines for severe inflammatory conditions through a proprietary mesenchymal lineage cell therapy platform. Its commercial and pipeline updates center on Ryoncil® (remestemcel-L-rknd), an FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, and on additional cell therapy programs for chronic low back pain, heart failure, Duchenne muscular dystrophy and inflammatory or autoimmune diseases.
Recurring company news covers Ryoncil launch and revenue trends, clinical and regulatory developments involving rexlemestrocel-L and Ryoncil label-extension programs, FDA clearances and designations, R&D presentations, technology licensing and platform expansion such as CAR-engineered MSC products, and quarterly cash-flow reporting filed with the Australian Securities Exchange.
Mesoblast (Nasdaq: MESO; ASX: MSB) presented its commercial business and development priorities at the ASX Investor Day in Melbourne. The session, “Meet the CEO: Inside Australia’s Listed Companies,” covered Ryoncil and the company’s cellular therapy platform.
Mesoblast outlined priorities including expanding Ryoncil into adult acute graft-versus-host disease and advancing rexlemestrocel-L for inflammatory chronic low back pain, end-stage heart failure and pulmonary hypertension related to left ventricular function. The presentation will be available on the ASX Investor Day resources page and Mesoblast’s investor website.
Mesoblast (Nasdaq: MESO; ASX: MSB) hosted a webinar highlighting Ryoncil’s use as first-line treatment after steroids for pediatric acute graft-versus-host disease. Dr. Susan Prockop, a pediatric transplant and cellular-therapy specialist at Boston Children’s Hospital and Harvard Medical School, discussed clinical practice, case studies and pivotal trial results.
Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older. A replay of the webinar is available.
Mesoblast (Nasdaq: MESO) announced board retirements and committee leadership changes, alongside plans to recruit directors with commercial biopharmaceutical experience.
William Burns will retire at the 2026 Annual General Meeting after serving since 2014. Jane Bell will take over as Chair of the Nomination and Remuneration Committee, having co-chaired with Burns since April 2026. Philip Krause, a director since 2022, will also retire. Mesoblast plans to appoint directors with U.S. and global commercial expertise to align the board with its revenue-generating business following RYONCIL's U.S. launch.
Mesoblast (MESO) reported RYONCIL net revenue growth of 44% for its first fiscal quarter ended September 30, 2026. Revenue was US$28 million, subject to financial closing procedures and audit. Operating cash spend fell 86% to US$2.1 million from US$14.9 million a year earlier; quarter-end cash was US$99 million.
The adult RYONCIL registration trial began enrolling patients, and FDA approved an additional potency assay supporting manufacturing scale-up. Treatment of all enrolled patients in the 350-patient Phase 3 rexlemestrocel-L low-back-pain trial was completed, with its 12-month durable pain-reduction endpoint due to read out next year. FDA confirmed a biologics license application for rexlemestrocel-L may proceed for life-threatening major gastrointestinal bleeding in end-stage heart-failure patients supported by a left ventricular assist device. Formal meeting minutes are expected shortly.
Mesoblast (MESO) has received FDA approval to use a new potency test for commercial Ryoncil batches.
The T-cell Proliferation Inhibition BioAssay (TIBA) will be used to release and monitor the stability of all new commercial lots alongside existing potency assays. Ryoncil is approved for steroid-refractory acute graft-versus-host disease in patients aged 2 months or older.
Mesoblast (Nasdaq:MESO; ASX:MSB) reported FY2026 total revenue of US$120.3 million, up sharply from US$17.2 million a year earlier, driven by the first full U.S. commercial year of Ryoncil, which generated net product revenue of US$115.2 million after a 13.4% gross-to-net adjustment.
Reported gross profit was US$103.6 million, with gross profit excluding amortization of US$109.7 million versus US$16.0 million in FY2025. The net loss narrowed 44% to US$57.5 million, and net operating cash spend fell to US$43.8 million. Year-end cash was US$103 million, supported by a new US$125 million five-year non-dilutive credit facility that refinanced higher-cost debt. Operationally, Mesoblast expanded Ryoncil uptake across >50 U.S. pediatric transplant centers, advanced label expansion programs into adults with SR-aGvHD and children with Duchenne muscular dystrophy, completed treatment of 350 patients in a pivotal Phase 3 chronic low back pain trial of rexlemestrocel-L, and progressed a BLA for LVAD-associated gastrointestinal bleeding, while launching next-generation CAR-MSC and OV-MSC platform initiatives.
Mesoblast (Nasdaq:MESO, ASX:MSB) will host a webcast to review operational highlights and financial results for the full year ended June 30, 2026. The webcast begins at 6:30pm EDT on Wednesday, August 26 and 8:30am AEST on Thursday, August 27, 2026, accessible at https://webcast.openbriefing.com/msb-fyr-2026/, with an archived version on the company’s investor page.
Mesoblast develops allogeneic cellular medicines from its mesenchymal lineage cell therapy platform. Its product Ryoncil (remestemcel-L-rknd) is described as the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD, and the company advances additional indications and candidates including rexlemestrocel-L.
Mesoblast (Nasdaq:MESO; ASX:MSB) reported completion of patient treatment in its pivotal randomized, controlled Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. A total of 350 patients were randomized to receive either an intra-discal injection of rexlemestrocel-L or a sham injection, up from 300 after strong investigator demand.
The trial’s 12‑month primary endpoint is durable pain reduction from a single injection, aiming to confirm results seen in the earlier MSB-DR003 trial. Secondary endpoints include function, quality of life, and reduction or cessation of pain medication, including opioids. According to Mesoblast, with 350 treated patients the study is well-powered to detect greater benefit versus controls. Rexlemestrocel-L holds FDA RMAT designation for CLBP due to degenerative disc disease, making it eligible for priority review once a BLA is filed. Top-line Phase 3 results are expected in mid‑CY2027. Mesoblast estimates CLBP from degenerative disc disease affects over 7 million people in the U.S. and cites potential peak year revenue of more than US$10 billion for this indication at single-digit market penetration.
Mesoblast (Nasdaq:MESO; ASX:MSB) reported preliminary Ryoncil® net revenue of US$36 million for the June 2026 quarter and US$115 million for the first full year post-FDA approval, including US$66.5 million in the second half. Net operating cash spend for FY2026 was US$43.8 million, with US$13.4 million in the second half, and cash on hand was US$103 million after drawing US$50 million from a five-year facility to extinguish all maturing debt.
Operationally, Mesoblast is running a registrational trial to extend Ryoncil’s label to adults with steroid-refractory acute GvHD and received FDA IND clearance for a registrational trial in ambulatory children with Duchenne muscular dystrophy. The company also completed enrollment of at least 300 patients in a pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, obtained a BLA filing number and requested modular review for rexlemestrocel-L in LVAD-associated GI bleeding prevention, and licensed a CAR-MSC platform targeting inflammatory bowel disease and B cell autoimmune conditions.
Mesoblast (Nasdaq:MESO; ASX:MSB) announced it has reached its target of at least 300 treated patients in the MSB-DR004 pivotal Phase 3 randomized, placebo-controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
The trial aims to confirm durable pain reduction from a single intra-discal injection seen in the earlier MSB-DR003 study. The primary endpoint is reduction in low back pain at 12 months versus sham control, with secondary endpoints including function, quality of life, and cessation of pain medication, including opioids. Rexlemestrocel-L has RMAT designation from the FDA, enabling eligibility for priority review once a BLA is filed. Mesoblast is progressing commercial manufacturing in parallel, with top-line Phase 3 results expected in mid‑CY2027. The CLBP indication is described by Mesoblast as a potential blockbuster with possible peak year revenue >US$10 billion at single-digit market penetration.